Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

Author's Avatar
Jul 27, 2021

Infinity+Pharmaceuticals%2C+Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update.